AR038183A1 - Peptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c - Google Patents
Peptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis cInfo
- Publication number
- AR038183A1 AR038183A1 ARP030100131A ARP030100131A AR038183A1 AR 038183 A1 AR038183 A1 AR 038183A1 AR P030100131 A ARP030100131 A AR P030100131A AR P030100131 A ARP030100131 A AR P030100131A AR 038183 A1 AR038183 A1 AR 038183A1
- Authority
- AR
- Argentina
- Prior art keywords
- present
- alkyl
- absent
- chr
- cycloalkyl
- Prior art date
Links
- 101800001098 Serine protease NS3 Proteins 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 229910052717 sulfur Inorganic materials 0.000 abstract 7
- 125000004122 cyclic group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- -1 aryl-heteroaryl Chemical group 0.000 abstract 5
- 125000004104 aryloxy group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- 125000001769 aryl amino group Chemical group 0.000 abstract 3
- 125000005110 aryl thio group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 2
- 239000004365 Protease Substances 0.000 abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 2
- 150000001299 aldehydes Chemical class 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003368 amide group Chemical group 0.000 abstract 2
- 239000004202 carbamide Substances 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000002576 ketones Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 229940100389 Sulfonylurea Drugs 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 abstract 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 abstract 1
- 125000005248 alkyl aryloxy group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- UTXKJLXAUOOWAC-UHFFFAOYSA-N azanylidyne-[[cyano(nitrosulfonyl)sulfinamoyl]-nitrosulfonylamino]methane Chemical compound [O-][N+](=O)S(=O)(=O)N(C#N)S(=O)N(C#N)S(=O)(=O)[N+]([O-])=O UTXKJLXAUOOWAC-UHFFFAOYSA-N 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000005518 carboxamido group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004437 phosphorous atom Chemical group 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- 150000003457 sulfones Chemical class 0.000 abstract 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/052,386 US7244721B2 (en) | 2000-07-21 | 2002-01-18 | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038183A1 true AR038183A1 (es) | 2005-01-05 |
Family
ID=27609106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100131A AR038183A1 (es) | 2002-01-18 | 2003-01-17 | Peptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7244721B2 (https=) |
| EP (1) | EP1481000B1 (https=) |
| JP (1) | JP4563033B2 (https=) |
| KR (1) | KR101020355B1 (https=) |
| CN (2) | CN1633446A (https=) |
| AR (1) | AR038183A1 (https=) |
| AT (1) | ATE469914T1 (https=) |
| AU (1) | AU2009210423B2 (https=) |
| BR (1) | BR0306931A (https=) |
| CA (1) | CA2473032A1 (https=) |
| CO (1) | CO5650168A2 (https=) |
| CY (1) | CY1111225T1 (https=) |
| DE (1) | DE60332814D1 (https=) |
| DK (1) | DK1481000T3 (https=) |
| EC (1) | ECSP045191A (https=) |
| IL (1) | IL162815A0 (https=) |
| MX (1) | MXPA04006934A (https=) |
| MY (1) | MY140710A (https=) |
| NO (1) | NO20042792L (https=) |
| NZ (1) | NZ571073A (https=) |
| PE (1) | PE20030852A1 (https=) |
| PL (1) | PL372747A1 (https=) |
| PT (1) | PT1481000E (https=) |
| RU (1) | RU2404189C9 (https=) |
| SI (1) | SI1481000T1 (https=) |
| TW (1) | TWI334872B (https=) |
| WO (1) | WO2003062265A2 (https=) |
| ZA (1) | ZA200405304B (https=) |
Families Citing this family (164)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP1019A (en) | 1996-10-18 | 2001-10-16 | Vertex Pharma | Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease. |
| CN1498224A (zh) | 2000-07-21 | 2004-05-19 | ���鹫˾ | 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽 |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| JP2003007697A (ja) * | 2001-06-21 | 2003-01-10 | Hitachi Kokusai Electric Inc | 半導体装置の製造方法、基板処理方法および基板処理装置 |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| SG185140A1 (en) | 2003-06-17 | 2012-11-29 | Merck Sharp & Dohme | Enantiomer forms of boc protected 3-amino-3-cyclobutylmethyl-2-hydroxy-propionamide |
| AR044694A1 (es) * | 2003-06-17 | 2005-09-21 | Schering Corp | Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo |
| EP1633711B1 (en) * | 2003-06-17 | 2010-11-24 | Schering Corporation | Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof |
| WO2005021584A2 (en) * | 2003-08-26 | 2005-03-10 | Schering Corporation | Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus |
| UY28500A1 (es) | 2003-09-05 | 2005-04-29 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc. |
| JP4525982B2 (ja) * | 2003-09-26 | 2010-08-18 | シェーリング コーポレイション | Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼの大環状インヒビター |
| US20110150835A1 (en) * | 2003-09-26 | 2011-06-23 | Schering Corporation | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease |
| US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| BRPI0416902A (pt) | 2003-12-11 | 2007-01-16 | Schering Corp | inibidores de ns3/ns4a serina protease do vìrus da hepatite c |
| PL1713822T3 (pl) | 2004-01-30 | 2010-08-31 | Medivir Ab | Inhibitory proteazy serynowej HCV NS-3 |
| WO2005077969A2 (en) * | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| HRP20130971T1 (hr) | 2004-02-20 | 2013-11-08 | Boehringer Ingelheim International Gmbh | Inhibitori virusne polimeraze |
| CN103102389A (zh) * | 2004-02-27 | 2013-05-15 | 默沙东公司 | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物 |
| CN1946690A (zh) * | 2004-02-27 | 2007-04-11 | 先灵公司 | 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的含环丁烯二酮基团化合物 |
| WO2005087721A2 (en) * | 2004-02-27 | 2005-09-22 | Schering Corporation | Compounds as inhibitors of hepatitis c virus ns3 serine protease |
| DE602005015834D1 (de) | 2004-02-27 | 2009-09-17 | Schering Corp | 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
| EP1730165A1 (en) * | 2004-02-27 | 2006-12-13 | Schering Corporation | Inhibitors of hepatitis c virus ns3 protease |
| AU2005219824B2 (en) | 2004-02-27 | 2007-11-29 | Merck Sharp & Dohme Corp. | Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus |
| US7816326B2 (en) * | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
| EP1737881B1 (en) * | 2004-02-27 | 2009-06-24 | Schering Corporation | Novel compounds as inhibitors of hepatitis c virus ns3 serine protease |
| US20050249702A1 (en) * | 2004-05-06 | 2005-11-10 | Schering Corporation | (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease |
| DE602005015452D1 (de) * | 2004-05-20 | 2009-08-27 | Schering Corp | Substituierte proline als hemmer der ns3-serinprotease des hepatits-c-virus |
| CA2590962A1 (en) | 2004-12-06 | 2006-06-15 | Siga Technologies, Inc. | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
| GB0426661D0 (en) * | 2004-12-06 | 2005-01-05 | Isis Innovation | Pyrrolidine compounds |
| US8410149B2 (en) | 2004-12-06 | 2013-04-02 | Siga Technologies Inc. | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
| US7994221B2 (en) | 2004-12-06 | 2011-08-09 | Siga Technologies, Inc. | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
| US20060276404A1 (en) * | 2005-06-02 | 2006-12-07 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
| JP2008545748A (ja) * | 2005-06-02 | 2008-12-18 | シェーリング コーポレイション | Ｃ型肝炎ウイルスに関連する障害を処置するために有用な徐放処方物 |
| US20060275366A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
| US20060281689A1 (en) * | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
| NZ563365A (en) * | 2005-06-02 | 2011-02-25 | Schering Corp | Combination of HCV protease inhibitors with a surfactant |
| US20070021351A1 (en) * | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
| WO2006130552A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| US20060276405A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis C |
| NZ563361A (en) * | 2005-06-02 | 2011-02-25 | Schering Corp | HCV protease inhibitors in combination with food |
| WO2006130554A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| US7608592B2 (en) * | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
| AU2006276246B2 (en) * | 2005-07-25 | 2012-09-27 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| WO2007022459A2 (en) * | 2005-08-19 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| US8399615B2 (en) * | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| ES2356776T3 (es) | 2005-10-11 | 2011-04-13 | Intermune, Inc. | Compuestos y métodos para inhibir la replicación del virus de la hepatitis. |
| AR056805A1 (es) * | 2005-11-14 | 2007-10-24 | Schering Corp | Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados |
| JP5247466B2 (ja) * | 2005-12-22 | 2013-07-24 | メルク・シャープ・アンド・ドーム・コーポレーション | ６，６−ジメチル−３−アザビシクロ−［３．１．０］−ヘキサン化合物およびその鏡像異性体塩を調製するプロセス |
| UA96283C2 (uk) | 2005-12-23 | 2011-10-25 | Зіланд Фарма А/С | Модифіковані міметики лізину |
| US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| AU2007217355B2 (en) | 2006-02-27 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same |
| WO2007109080A2 (en) | 2006-03-16 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
| AU2007249668B2 (en) * | 2006-04-11 | 2011-04-07 | Novartis Ag | HCV/HIV inhibitors and their uses |
| WO2007120595A2 (en) * | 2006-04-11 | 2007-10-25 | Novartis Ag | Amines for the treatment of hcv |
| US7951823B2 (en) * | 2006-05-23 | 2011-05-31 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| RU2009109355A (ru) | 2006-08-17 | 2010-09-27 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Ингибиторы вырусной полимеразы |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) * | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100081672A1 (en) * | 2006-12-07 | 2010-04-01 | Schering Corporation | Ph sensitive matrix formulation |
| PL2468724T3 (pl) | 2006-12-21 | 2016-05-31 | Zealand Pharma As | Synteza związków pirolidynowych |
| WO2008074035A1 (en) | 2006-12-27 | 2008-06-19 | Abbott Laboratories | Hcv protease inhibitors and uses thereof |
| EA016327B1 (ru) * | 2007-02-09 | 2012-04-30 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
| WO2008106058A2 (en) * | 2007-02-27 | 2008-09-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| HRP20120330T1 (hr) | 2007-02-27 | 2012-05-31 | Vertex Pharmaceuticals Incorporated | Sukristali i farmaceutski pripravci koji ih sadrže |
| EP2139854A2 (en) * | 2007-03-23 | 2010-01-06 | Schering Corporation | P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease |
| SG174809A1 (en) * | 2007-05-03 | 2011-10-28 | Intermune Inc | Macrocyclic compounds useful as inhibitors of hepatitis c virus |
| JP2010526834A (ja) * | 2007-05-10 | 2010-08-05 | インターミューン・インコーポレーテッド | Ｃ型肝炎ウイルス複製の新規ペプチド阻害剤 |
| ATE524466T1 (de) | 2007-07-03 | 2011-09-15 | Actelion Pharmaceuticals Ltd | 3-azabicycloä3.3.0üoktanverbindungen |
| KR20100046047A (ko) | 2007-07-27 | 2010-05-04 | 액테리온 파마슈티칼 리미티드 | 2-아자-비시클로[3.3.0]옥탄 유도체 |
| US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| NZ583699A (en) | 2007-08-30 | 2012-04-27 | Vertex Pharma | Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same |
| CN101868452B (zh) | 2007-10-10 | 2014-08-06 | 诺华股份有限公司 | 螺环吡咯烷类与其对抗hcv和hiv感染的应用 |
| EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| CA2710236A1 (en) * | 2007-12-21 | 2009-07-09 | Schering Corporation | Process for the synthesis of 3-amino-3-cyclobutylmethyl-2-hydroxypropionamide or salts thereof |
| CA2720275A1 (en) | 2008-04-01 | 2009-10-08 | Astellas Pharma Inc. | Indolinone compound |
| WO2009142842A2 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2300491B1 (en) | 2008-05-29 | 2016-01-06 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| JP2011522860A (ja) | 2008-06-10 | 2011-08-04 | ノバルティス アーゲー | 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体 |
| CN102816106A (zh) | 2008-06-24 | 2012-12-12 | 默沙东公司 | 用于制备基本上立体异构纯的稠合二环脯氨酸化合物的生物催化方法 |
| AU2009266318A1 (en) * | 2008-07-03 | 2010-01-07 | Vertex Pharmaceuticals Incorporated | Preparation of protected alpha-keto beta-amino esters and amides |
| US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102271699A (zh) | 2009-01-07 | 2011-12-07 | 西尼克斯公司 | 用于治疗hcv和hiv感染的环孢菌素衍生物 |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| US8512690B2 (en) * | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| US20120244122A1 (en) | 2009-05-28 | 2012-09-27 | Masse Craig E | Peptides for the Treatment of HCV Infections |
| CA2763140A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
| AR077139A1 (es) | 2009-06-23 | 2011-08-03 | Gilead Sciences Inc | Composiciones farmaceuticas utiles para tratar el vch |
| PL2477980T3 (pl) | 2009-09-15 | 2017-02-28 | Taigen Biotechnology Co., Ltd. | Inhibitory proteazy hcv |
| CN102741270B (zh) * | 2009-09-28 | 2015-07-22 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
| JP2013512246A (ja) | 2009-11-25 | 2013-04-11 | メルク・シャープ・アンド・ドーム・コーポレーション | ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体 |
| US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
| WO2011103933A1 (en) | 2010-02-25 | 2011-09-01 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg | PROCESS FOR THE PREPARATION OF α-ACYLOXY β-FORMAMIDO AMIDES |
| EA201290882A1 (ru) | 2010-03-09 | 2013-04-30 | Мерк Шарп Энд Домэ Корп. | Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний |
| WO2012018534A2 (en) | 2010-07-26 | 2012-02-09 | Schering Corporation | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| JP2013540122A (ja) | 2010-09-29 | 2013-10-31 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法 |
| CN102010425B (zh) * | 2010-11-04 | 2013-04-10 | 山东大学 | 1,4-二硫-7-氮杂螺[4,4]壬烷-8-羧酸衍生物类组蛋白去乙酰化酶抑制剂及其应用 |
| BR112013026345A2 (pt) | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv |
| WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20130267699A1 (en) | 2011-06-24 | 2013-10-10 | California Institute Of Technology | Quaternary heteroatom containing compounds |
| US8822679B2 (en) * | 2011-06-24 | 2014-09-02 | California Institute Of Technology | Quaternary heteroatom containing compounds |
| WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
| US20140378416A1 (en) | 2011-09-14 | 2014-12-25 | Michael P. Dwyer | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| SE1450131A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| DE112012002748T5 (de) | 2011-10-21 | 2014-07-31 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| US20130123325A1 (en) | 2011-11-14 | 2013-05-16 | Sven Ruf | Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases |
| UA115542C2 (uk) * | 2011-12-23 | 2017-11-27 | Іпсен Мануфекчерінг Айрленд Лімітед | Процес синтезу терапевтичних пептидів |
| AR091192A1 (es) | 2012-05-30 | 2015-01-21 | Chemo Iberica Sa | Procedimiento multicomponente para la preparacion de compuestos biciclicos |
| WO2014053533A1 (en) | 2012-10-05 | 2014-04-10 | Sanofi | Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation |
| EA025560B1 (ru) | 2012-10-19 | 2017-01-30 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP3184095A1 (en) | 2013-05-23 | 2017-06-28 | IP Gesellschaft für Management mbH | Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
| CN103387510B (zh) * | 2013-08-08 | 2015-09-09 | 苏州永健生物医药有限公司 | 一种β-氨基-alpha-羟基环丁基丁酰胺盐酸盐的合成方法 |
| WO2015065817A1 (en) | 2013-10-30 | 2015-05-07 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
| TWI659019B (zh) | 2014-02-28 | 2019-05-11 | 日商帝人製藥股份有限公司 | 吡唑醯胺衍生物 |
| US10421696B2 (en) | 2014-12-18 | 2019-09-24 | California Institute Of Technology | Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation |
| US10106479B2 (en) | 2015-03-27 | 2018-10-23 | California Institute Of Technology | Asymmetric catalytic decarboxylative alkyl alkylation using low catalyst concentrations and a robust precatalyst |
| EP3426391A4 (en) | 2016-03-11 | 2019-08-28 | California Institute of Technology | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMEN |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| JP7164521B2 (ja) | 2016-06-21 | 2022-11-01 | オリオン・オフサルモロジー・エルエルシー | 炭素環式プロリンアミド誘導体 |
| CA3026505A1 (en) * | 2016-06-21 | 2017-12-28 | Orion Ophthalmology LLC | Aliphatic prolinamide derivatives |
| HUE064412T2 (hu) | 2016-06-21 | 2024-03-28 | Orion Ophthalmology LLC | Heterociklusos prolinamid-származékok |
| JP6989864B2 (ja) | 2017-05-05 | 2022-02-03 | ジーランド ファーマ，アー／エス | ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用 |
| EP3480190B1 (en) | 2017-11-01 | 2023-01-04 | California Institute of Technology | Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols |
| EP3699173A1 (en) | 2018-10-18 | 2020-08-26 | California Institute of Technology | Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same |
| CA3180177A1 (en) * | 2020-05-08 | 2021-11-11 | The Board Of Trustees Of The Leland Stanford Junior University | Protease inhibitors for treatment or prevention of coronavirus disease |
| CA3189027A1 (en) | 2020-07-11 | 2022-01-20 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| US20240217930A1 (en) * | 2021-04-01 | 2024-07-04 | Heptares Therapeutics Limited | Sars-cov-2 mpro inhibitor compounds |
| JP2024525589A (ja) | 2021-07-09 | 2024-07-12 | アリゴス セラピューティクス インコーポレイテッド | 抗ウイルス化合物 |
| CN114149415A (zh) * | 2021-07-26 | 2022-03-08 | 中国药科大学 | 一种拟肽类化合物及其衍生物、制备方法、药物组合物和应用 |
| CN117836272B (zh) * | 2021-08-02 | 2025-02-28 | 北京华益健康药物研究中心 | 用于治疗或预防冠状病毒感染的3cl蛋白酶小分子抑制剂及其用途 |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| EP4460508A4 (en) * | 2022-01-07 | 2025-12-24 | Merck Sharp & Dohme Llc | PROTEASE INHIBITORS TO TREAT OR PREVENT CORONAVIRUS INFECTION |
| EP4649086A1 (en) * | 2023-01-09 | 2025-11-19 | Merck Sharp & Dohme LLC | Protease inhibitors for treating or preventing coronavirus infection |
| WO2025201636A1 (en) | 2023-03-31 | 2025-10-02 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA86746B (en) | 1985-02-04 | 1986-09-24 | Merrell Dow Pharma | Novel peptidase inhibitors |
| US5496927A (en) | 1985-02-04 | 1996-03-05 | Merrell Pharmaceuticals Inc. | Peptidase inhibitors |
| NZ227011A (en) | 1987-11-18 | 1992-03-26 | Chiron Corp | Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits |
| ZA897515B (en) | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
| EP0381216B1 (en) | 1989-02-01 | 1995-12-27 | Asahi Glass Company Ltd. | Hydrochlorofluorocarbon azeotropic or azeotropic-like mixture |
| US5359138A (en) | 1989-04-15 | 1994-10-25 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Poststatin and related compounds or salts thereof |
| EP0672648B1 (en) | 1989-04-15 | 1998-09-23 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Threo (2R,3S)-3-amino-2-hydroxypentanoic acid and threo (2R,3S)-3-(p-methoxy-benzyloxycarbonyl/FMOC) amino-2-hydroxy-pentanoic acid |
| ATE270326T1 (de) | 1990-04-04 | 2004-07-15 | Chiron Corp | Protease von hepatitis-c-virus |
| JP2804817B2 (ja) | 1990-04-13 | 1998-09-30 | 財団法人微生物化学研究会 | ３―アミノ―２―オキソ脂肪酸誘導体の製造法 |
| JPH04149166A (ja) | 1990-10-12 | 1992-05-22 | Nippon Kayaku Co Ltd | 新規ケト酸アミド誘導体 |
| CA2098609A1 (en) | 1990-12-28 | 1992-06-29 | Raymond T. Bartus | Use of calpain inhibitors in the inhibition and treatment of neurodegeneration |
| EP0627000B1 (en) | 1992-01-31 | 2003-10-29 | Abbott Laboratories | Mammalian expression systems for hcv proteins |
| JPH09500087A (ja) | 1992-06-24 | 1997-01-07 | コーテックス ファーマシューティカルズ インコーポレイテッド | カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法 |
| US5514694A (en) | 1992-09-21 | 1996-05-07 | Georgia Tech Research Corp | Peptidyl ketoamides |
| US5414018A (en) | 1993-09-24 | 1995-05-09 | G. D. Searle & Co. | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension |
| US5843450A (en) | 1994-02-14 | 1998-12-01 | Abbott Laboratories | Hepatitis GB Virus synthetic peptides and uses thereof |
| IT1272179B (it) | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
| US5500208A (en) | 1994-06-07 | 1996-03-19 | The Procter & Gamble Company | Oral compositions comprising a novel tripeptide |
| US5843752A (en) | 1995-05-12 | 1998-12-01 | Schering Corporation | Soluble active hepatitis C virus protease |
| US5919765A (en) | 1995-06-07 | 1999-07-06 | Cor Therapeutics, Inc. | Inhibitors of factor XA |
| GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
| US5763576A (en) | 1995-10-06 | 1998-06-09 | Georgia Tech Research Corp. | Tetrapeptide α-ketoamides |
| IL120310A (en) | 1996-03-01 | 2002-02-10 | Akzo Nobel Nv | Serine protease inhibitors and pharmaceuticals containing them |
| US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| IT1285158B1 (it) | 1996-09-17 | 1998-06-03 | Angeletti P Ist Richerche Bio | Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il |
| WO1998013462A1 (en) | 1996-09-24 | 1998-04-02 | The Procter & Gamble Company | Liquid detergents containing proteolytic enzyme, peptide aldehyde and a source of boric acid |
| US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
| AP1019A (en) | 1996-10-18 | 2001-10-16 | Vertex Pharma | Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease. |
| DE69728164D1 (de) | 1996-12-27 | 2004-04-22 | Boehringer Ingelheim Ca Ltd | Peptidomimetische inhibitoren von der protease des menschlichen cytomegalovirus |
| WO1998037180A2 (en) | 1997-02-22 | 1998-08-27 | Abbott Laboratories | Hcv fusion protease and polynucleotide encoding same |
| EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
| ES2241157T3 (es) | 1997-08-11 | 2005-10-16 | Boehringer Ingelheim (Canada) Ltd. | Peptidos inhibidores de la hepatitis c. |
| GB9809664D0 (en) | 1998-05-06 | 1998-07-01 | Hoffmann La Roche | a-Ketoamide derivatives |
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| US6576613B1 (en) * | 1998-07-24 | 2003-06-10 | Corvas International, Inc. | Title inhibitors of urokinase |
| JP2000256396A (ja) | 1999-03-03 | 2000-09-19 | Dainippon Pharmaceut Co Ltd | 複素環式化合物およびその中間体ならびにエラスターゼ阻害剤 |
| US6774212B2 (en) | 1999-12-03 | 2004-08-10 | Bristol-Myers Squibb Pharma Company | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease |
| AU2001251165A1 (en) | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| ES2317900T3 (es) * | 2000-04-05 | 2009-05-01 | Schering Corporation | Inhibidores de serina proteasa ns3 macrociclicos del virus de la hepatitis c que comprenden fragmentos n-ciclicas p2. |
| CN1498224A (zh) * | 2000-07-21 | 2004-05-19 | ���鹫˾ | 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽 |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
-
2002
- 2002-01-18 US US10/052,386 patent/US7244721B2/en not_active Expired - Lifetime
-
2003
- 2003-01-16 AT AT03731956T patent/ATE469914T1/de active
- 2003-01-16 TW TW092100868A patent/TWI334872B/zh not_active IP Right Cessation
- 2003-01-16 DK DK03731956.3T patent/DK1481000T3/da active
- 2003-01-16 IL IL16281503A patent/IL162815A0/xx unknown
- 2003-01-16 EP EP03731956A patent/EP1481000B1/en not_active Expired - Lifetime
- 2003-01-16 PL PL03372747A patent/PL372747A1/xx not_active IP Right Cessation
- 2003-01-16 CA CA002473032A patent/CA2473032A1/en not_active Abandoned
- 2003-01-16 PE PE2003000049A patent/PE20030852A1/es not_active Application Discontinuation
- 2003-01-16 CN CNA038059339A patent/CN1633446A/zh active Pending
- 2003-01-16 DE DE60332814T patent/DE60332814D1/de not_active Expired - Lifetime
- 2003-01-16 BR BR0306931-1A patent/BR0306931A/pt not_active IP Right Cessation
- 2003-01-16 PT PT03731956T patent/PT1481000E/pt unknown
- 2003-01-16 RU RU2004125279/04A patent/RU2404189C9/ru not_active IP Right Cessation
- 2003-01-16 CN CN201010143451A patent/CN101792483A/zh active Pending
- 2003-01-16 MX MXPA04006934A patent/MXPA04006934A/es active IP Right Grant
- 2003-01-16 JP JP2003562142A patent/JP4563033B2/ja not_active Expired - Fee Related
- 2003-01-16 MY MYPI20030137A patent/MY140710A/en unknown
- 2003-01-16 SI SI200331853T patent/SI1481000T1/sl unknown
- 2003-01-16 WO PCT/US2003/001430 patent/WO2003062265A2/en not_active Ceased
- 2003-01-16 KR KR1020047011022A patent/KR101020355B1/ko not_active Expired - Fee Related
- 2003-01-16 NZ NZ571073A patent/NZ571073A/en not_active IP Right Cessation
- 2003-01-17 AR ARP030100131A patent/AR038183A1/es unknown
-
2004
- 2004-07-02 ZA ZA200405304A patent/ZA200405304B/en unknown
- 2004-07-02 NO NO20042792A patent/NO20042792L/no not_active Application Discontinuation
- 2004-07-15 EC EC2004005191A patent/ECSP045191A/es unknown
- 2004-07-16 CO CO04068146A patent/CO5650168A2/es not_active Application Discontinuation
-
2007
- 2007-03-06 US US11/714,457 patent/US7592316B2/en not_active Expired - Lifetime
-
2009
- 2009-08-21 AU AU2009210423A patent/AU2009210423B2/en not_active Ceased
-
2010
- 2010-09-01 CY CY20101100797T patent/CY1111225T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038183A1 (es) | Peptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c | |
| AR038214A1 (es) | Compuestos de prolina como inhibidores de la serina proteasa ns3 del virus de la hepatitis c | |
| AR033985A1 (es) | Peptidos inhibidores de proteasa serina-ns3 del virus de la hepatitis c, composicion farmaceutica que los comprende, un metodo para su preparacion, uso de los mismos para la fabricacion de un medicamento y un metodo de modulacion de la actividad de la proteasa del virus de la hepatitis c | |
| AR045497A1 (es) | Inhibidores peptidomimeticos de la serina proteasa ns3 del virus de la hepatitis c | |
| AR047903A1 (es) | Compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
| AR047901A1 (es) | Inhibidores de proteasa ns3 del virus de la hepatitis c | |
| AR048241A1 (es) | Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c . | |
| AR048023A1 (es) | Cetoamidas con p4 ciclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
| AR046758A1 (es) | Inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c | |
| AR048413A1 (es) | Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
| RU2336275C2 (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция | |
| AR029903A1 (es) | Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c, que comprenden partes p2 n-ciclicas, composiciones farmaceuticas y utilizacion de los mismos para la manufactura de un medicamento | |
| AR040476A1 (es) | N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina) | |
| AR046166A1 (es) | Inhibidores macrociclicos de la serina proteasa ns3 del virus de la hepatitis c | |
| AR030558A1 (es) | COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA, | |
| BG106566A (en) | Aromatic nitrogenous six-membered ring compounds | |
| AR030186A1 (es) | Compuesto antibacteriano 3-aminoquinazolina-2,4-diona, composicion farmaceutica que lo comprende y su uso para fabricarla | |
| AR059429A1 (es) | Combinaciones que involucran el (los) inhibidor(es) de la protesa hcv y metodos de tratamiento relacionados al (los) mismo (s) | |
| AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
| RU2003105217A (ru) | Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с | |
| AR055198A1 (es) | Formulaciones farmaceuticas y metodos de tratamiento que las utilizan | |
| AR039649A1 (es) | Compuestos de pirrolo-triazina anilina utiles como inhibidores de cinasa y las composiciones farmaceuticas que las contienen | |
| AR054197A1 (es) | Medicamentos y metodos combinando un inhibidor de la proteasa hcv y un competidor akr | |
| AR047339A1 (es) | Derivados de difenilazetidona.proceso de obtencion. | |
| AR031905A1 (es) | Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |